Publications

2019

Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30(Suppl_8):viii16-viii22.
Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, et al. TKI-resistant -rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations. Lung Cancer (Auckl). 2019;10:81-86.
Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, et al. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing . J Clin Microbiol. 2019;57(5).
Kabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, et al. AKT1 quiescent cancer cells in ductal carcinoma in situ of the breast. NPJ Breast Cancer. 2019;5:10.
Oriakhi M, Ortiz-Diaz E, Olibrice M, Ahluwalia M, Chadburn A, Shostak E. Endobronchial Obstruction by a Solitary Extramedullary Plasmacytoma With Light-chain Amyloidosis. J Bronchology Interv Pulmonol. 2019;26(2):e24-e26.
Son DH, Doan KV, Yang DJ, Sun JS, Kim SK, Kang N, et al. FoxO1 regulates leptin-induced mood behavior by targeting tyrosine hydroxylase. Metabolism. 2019;91:43-52.
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11428-11436.
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408-412.
Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJ. Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia. Br J Haematol. 2019;186(6):801.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700